Acorda Therapeutics, Inc. short interest in 2024

In 2024, Acorda Therapeutics, Inc.'s disclosed short interest ran from 0.98% of shares outstanding on 12 Jan 2024 to 0.65% on 28 Mar 2024, a change of -0.33 percentage points. The year's high was 0.98% on 12 Jan 2024 and its low 0.65% on 28 Mar 2024, averaging 0.83% across 6 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.49 days on 15 Feb 2024. Full history: Acorda Therapeutics, Inc..

Cite this page

Plain

Short position data for Acorda Therapeutics, Inc. short interest in 2024: FINRA, compiled by howshorted.com, settlement date 28 Mar 2024. https://howshorted.com/us/company/acorq-2024/2024/

Wikipedia

<ref>{{cite web |title=Acorda Therapeutics, Inc. short interest in 2024 short position data |url=https://howshorted.com/us/company/acorq-2024/2024/ |website=HowShorted |publisher=howshorted.com (data: FINRA) |date=2024-03-28 |access-date=2026-10-13}}</ref>

BibTeX

@misc{howshorted-acorda-therapeutics-inc-short-interest-i-2024-03-28,
  title        = {Acorda Therapeutics, Inc. short interest in 2024 short position data},
  author       = {{HowShorted}},
  howpublished = {\url{https://howshorted.com/us/company/acorq-2024/2024/}},
  note         = {Data: FINRA, settlement date 28 Mar 2024; accessed 2026-10-13},
  year         = {2024}
}

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

2024 in figures

Start of year: 0.98% (12 Jan 2024)
End of year: 0.65% (28 Mar 2024)
Change: -0.33 pp
High: 0.98% (12 Jan 2024)
Low: 0.65% (28 Mar 2024)
Average: 0.83%
Highest days to cover: 6.49 (15 Feb 2024)
SEC filings marked: 2

Every report in 2024

Acorda Therapeutics, Inc. short interest in 2024
Settlement	Short interest	Days to cover
12 Jan 2024	0.98%	3.30
31 Jan 2024	0.86%	2.26
15 Feb 2024	0.83%	6.49
29 Feb 2024	0.89%	3.90
15 Mar 2024	0.76%	1.69
28 Mar 2024	0.65%	2.34

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.